[1] Min XY, Xu ST, Xu WB. Advance in epidemiological researches and related vaccines of herpes zoster. Chin J Virol, 2020; 36, 109−14. (In Chinese)
[2] Gater A, Abetz-Webb L, Carroll S, et al. Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study. BMC Infect Dis, 2014; 14, 402. doi:  10.1186/1471-2334-14-402
[3] Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open, 2014; 4, e004833. doi:  10.1136/bmjopen-2014-004833
[4] Zhou H, Wang SQ, Chu Y, et al. Survey of seroprevalence of varicella zoster virus in healthy population in Shanghai. Chin J Vaccines Immun, 2006; 12, 137−9. (In Chinese)
[5] Suo LD, Zhao D, Chen M, et al. An investigation on serum antibody level of varicella-zoster virus in healthy population in Beijing. Chin J Vaccines Immun, 2022; 56, 108−13. (In Chinese)
[6] Jiang W, Li GW, Xu Y, et al. Epidemiological characteristics of herpes zoster in urban areas of Yichang city during 2016-2017 based on the Yichang Big Data Platform for Health Management. Chin J Vaccines Immun, 2019; 25, 432−5. (In Chinese)
[7] Zhang WY, Liu SN, Sun HY, et al. Study of incidence and economic burden of herpes zoster based on community investigation among the aged in Laiwu district, Jinan city, Shandong Province of China. Chin J Prev Med, 2022; 56, 119−24. (In Chinese)
[8] Zhu Q, Zheng HZ, Qu HY, et al. Epidemiology of herpes zoster among adults aged 50 and above in Guangdong, China. Hum Vaccin Immunother, 2015; 11, 2113−8. doi:  10.1080/21645515.2015.1016672
[9] Sun XH, Wei Z, Lin HB, et al. Incidence and disease burden of herpes zoster in the population aged ≥ 50 years in China: data from an integrated health care network. J Infect, 2021; 82, 253−60.
[10] Li YX, Yin ZD, Shao ZJ, et al. Population-based surveillance for bacterial meningitis in China, September 2006-December 2009. Emerg Infect Dis, 2014; 20, 61−9.